Leuprorelin acetate affects adhesion molecule expression in human prostate cancer cells

International Journal of Oncology

Volumn 38, Issue 6, 2011, Pages 1501-1509

  Angelucci, Cristiana ^a   Lama, Gina ^a   Iacopino, Fortunata ^a   Sica, Gigliola ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

catenin; catenin; catenin; Dihydrotestosterone; E cadherin; Leuprorelin acetate; N cadherin; Prostate cancer

Indexed keywords

ALPHA CATENIN; ANDROSTANOLONE; BETA CATENIN; CAVEOLIN 1; CD44V6 ANTIGEN; CELL ADHESION MOLECULE; LEUPRORELIN; NERVE CELL ADHESION MOLECULE; PLAKOGLOBIN; SCATTER FACTOR RECEPTOR; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL STRAIN; CELL STRAIN LNCAP; CELL STRAIN PC 3; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS, HORMONAL; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LEUPROLIDE; MALE; PROSTATIC NEOPLASMS;

EID: 79955795757     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.998     Document Type: Article

References (42)

1. Mareel M and Leroy A: Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83: 337-376, 2003. (Pubitemid 36382891)
2. Stemmler MP: Cadherins in development and cancer. Mol Biosyst 4: 835-850, 2008.
3. Ozawa M, Ringwald M and Kemler R: Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule. Proc Natl Acad Sci USA 87: 4246-4250, 1990.
4. Birchmeier W and Behrens J: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198: 11-26, 1994. (Pubitemid 24159061)
5. Prasad S, Thraves P, Kuettel M and Dritschilo A: Cytoskeletal and adhesion protein changes during neoplastic progression of human prostate epithelial cells. Crit Rev Oncol Hematol 27: 69-79, 1998. (Pubitemid 28275510)
6. Giroldi LA, Shimazui T, Schalken JA, Yamasaki H and Bringuier PP: Classical cadherins in urological cancers. Morphologie 84: 31-38, 2000.
7. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W and van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66: 107-119, 1991. (Pubitemid 121001351)
8. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ and Schalken JA: Cadherin switching in human prostate cancer progression. Cancer Res 60: 3650-3654, 2000. (Pubitemid 30482189)
9. Tran NL, Nagle RB, Cress AE and Heimark RL: N-cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am J Pathol 155: 787-798, 1999. (Pubitemid 29426824)
10. Jiang W, Hiscox S, Matsumoto K and Nakamura T: Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29: 209-248, 1999. (Pubitemid 29158969)
11. Shibamoto S, Hayakawa M, Takeuchi K, et al: Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes Commun 1: 295-305, 1994.
12. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P and Ponta H: CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16: 3074-3086, 2002. (Pubitemid 35424194)
13. Lokeshwar BL, Lokeshwar VB and Block NL: Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res 15: 1191-1198, 1995.
14. Gu H, Shang P and Zhou C: Expression of CD44v6 and E-cadherin in prostate carcinoma and metastasis of prostate carcinoma. Zhonghua Nan Ke Xue 10: 32-34, 2004.
15. Aaltomaa S, Lipponen P, Ala-Opas M and Kosma VM: Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol 39: 138-144, 2001. (Pubitemid 32171179)
16. Cohen AW, Hnasko R, Schubert W and Lisanti MP: Role of caveolae and caveolins in health and disease. Physiol Rev 84: 1341-1379, 2004. (Pubitemid 39287953)
17. Miller WR, Scott WN, Morris R, Fraser HM and Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231-233, 1985. (Pubitemid 15194060)
18. Emons G, Schroeder B, Ortmann O, Westphalen S, Schulz KD and Schally AV: High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77: 1458-1464, 1993. (Pubitemid 24000896)
19. Emons G, Ortmann O, Becker M, et al: High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53: 5439-5446, 1993. (Pubitemid 23342164)
20. Qayum A, Gullick W, Clayton RC, Sikora K and Waxman J: The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 62: 96-99, 1990. (Pubitemid 20226453)
21. Limonta P, Dondi D, Moretti RM, Maggi R and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75: 207-212, 1992.
22. Sica G, Iacopino F, Robustelli della Cuna G, Marchetti P and Marini L: Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells. J Cancer Res Clin Oncol 120: 605-609, 1994. (Pubitemid 24281409)
23. Marini L, Iacopino F, Schinzari G, Robustelli della Cuna FS, Mantovani G and Sica G: Direct antiproliferative effect of triptorelin on human breast cancer cells. Anticancer Res 14: 1881-1886, 1994.
24. Sica G, Schinzari G, Angelucci C, Lama G and Iacopino F: Direct effects of GnRH agonists in human hormone-sensitive endometrial cells. Mol Cell Endocrinol 176: 121-128, 2001. (Pubitemid 32454943)
25. Sica G, Iacopino F, Settesoldi D and Zelano G: Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells. Eur Urol 35: 2-8, 1999. (Pubitemid 29078476)
26. Sica G, Zelano G, Settesoldi D and Iacopino F: Regulation of prostate-specific antigen gene expression by an LH-RH analogue in human prostatic cells. Anticancer Res 23: 1283-1287, 2003. (Pubitemid 36754089)
27. Iacopino F, Lama G, Angelucci C and Sica G: Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells. Int J Oncol 29: 237-247, 2006.
28. Angelucci C, Iacopino F, Lama G, et al: Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells. Anticancer Res 24: 2729-2738, 2004. (Pubitemid 39407150)
29. Angelucci C, Lama G, Iacopino F, Ferracuti S, Bono AV, Millar RP and Sica G: GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors. Endocrine 36: 87-97, 2009.
30. Peterson GL: A simplification of the protein assay method of Lowry et al which is more generally applicable. Anal Biochem 83: 346-356, 1977.
31. Sasaki H, Nio M, Iwami D, Funaki N, Ohi R and Sasano H: Cytokeratin subtypes in biliary atresia: immunohistochemical study. Pathol Int 51: 511-518, 2001. (Pubitemid 32744434)
32. Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA and Day ML: Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Res 61: 489-492, 2001. (Pubitemid 32128604)
33. Ito K, Okamoto I, Araki N, et al: Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from cell-cell contacts. Oncogene 18: 7080-7090, 1999. (Pubitemid 30028879)
34. Steinhusen U, Weiske J, Badock V, Tauber R, Bommert K and Huber O: Cleavage and shedding of E-cadherin after induction of apoptosis. J Biol Chem 276: 4972-4980, 2001.
35. Larue L, Ohsugi M, Hirchenhain J and Kemler R: E-cadherin null mutant embryos fail to form a trophoectoderm epithelium. Proc Natl Acad Sci USA 91: 8263-8267, 1994. (Pubitemid 24253927)
36. Nelson WJ, Shore EM, Wang AZ and Hammerton RW: Identification of a membrane-cytoskeletal complex containing the cell adhesion molecule uvomorulin (E-cadherin), ankyrin, and fodrin in Mardin-Darby canine kidney epithelial cells. J Cell Biol 110: 349-357, 1990.
37. Carruba G, Miceli D, D'Amico D, Farruggio R, Comito L, Montesanti A, Polito L and Castagnetta LA: Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells. Biochem Biophys Res Commun 212: 624-631, 1995.
38. Aoki M, Hecht A, Kruse U, Kemler R and Vogt PK: Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci USA 96: 139-144, 1999. (Pubitemid 29036066)
39. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR and Fearon ER: Gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 14: 1319-1331, 2000. (Pubitemid 30397076)
40. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN and Leung HY: Evidence that prostate gonadotropin-releasing hormone receptors mediates an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 206: 205-213, 2005. (Pubitemid 40754024)
41. Montagnani Marelli M, Moretti RM, Mai S, Procacci P and Limonta P: Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 30: 261-271, 2007.
42. Maudsley S, Davidson L, Pawson AJ, Freestone SH, López de Maturana R, Thomson AA and Millar RP: Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5. Neuroendocrinology 84: 285-300, 2006. (Pubitemid 46398356)